Eli Gelman - Amdocs CEO
| DOX Stock | USD 85.11 0.18 0.21% |
CEO
Mr. Eli Gelman serves as Director of the Company effective September 30, 2018. Mr. Gelman was a director of Amdocs since 2002. Mr. Gelman became the President and Chief Executive Officer of Amdocs Management Limited, our whollyowned subsidiary, in 2010. From 2010 until 2013, Mr. Gelman served as a director of Retalix, a global software company, and during 2010, he also served as its Chairman. From 2008 to 2010, Mr. Gelman devoted his time to charitable matters focused on youth education. He served as Executive Vice President of Amdocs Management Limited from 2002 until 2008 and as our Chief Operating Officer from 2006 until 2008. Prior to 2002, he was a Senior Vice President, where he headed our U.S. sales and marketing operations and helped spearhead our entry into the customer care and billing systems market. Before that, Mr. Gelman was an account manager for our major European and North American installations, and has led several major software development projects. Before joining Amdocs, Mr. Gelman was involved in the development of realtime software systems for communications networks and software projects for NASA. Mr. Gelmans qualifications to serve on our Board of Directors include his more than two decades of service to Amdocs and its customers, including as our Chief Operating Officer. With more than 30 years of experience in the software industry, he possesses a vast institutional knowledge and strategic understanding of our organization and industry. since 2018.
| Age | 58 |
| Tenure | 6 years |
| Address | 625 Maryville Centre Drive, Saint Louis, MO, United States, 63141 |
| Phone | 314 212 7000 |
| Web | https://www.amdocs.com |
Amdocs Management Efficiency
The company has Return on Asset of 0.071 % which means that on every $100 spent on assets, it made $0.071 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1562 %, implying that it generated $0.1562 on every 100 dollars invested. Amdocs' management efficiency ratios could be used to measure how well Amdocs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.10 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Amdocs' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 307 M in 2024, whereas Total Assets are likely to drop slightly above 4.5 B in 2024.Similar Executives
| Found 10 records | CEO Age | ||
| Ehud Mokady | CyberArk Software | 55 | |
| Jacques CPA | Global Blue Group | 60 | |
| Francois LocohDonou | F5 Networks | 53 | |
| Thomas Hook | Global Blue Group | 51 | |
| Anthony Casalena | Squarespace | 42 | |
| Morgan Schuessler | Evertec | 51 | |
| John McAdam | F5 Networks | 67 | |
| Bret Griess | CSG Systems International | 49 | |
| Stanley Leung | Global Blue Group | 47 | |
| Jacques Stern | Global Blue Group | 56 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.071 |
Amdocs Leadership Team
Elected by the shareholders, the Amdocs' board of directors comprises two types of representatives: Amdocs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amdocs. The board's role is to monitor Amdocs' management team and ensure that shareholders' interests are well served. Amdocs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amdocs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Sheffer, CEO President | ||
| Darcy Antonellis, Head Media | ||
| Oren Marmur, Head Network | ||
| Richard LeFave, Independent Director | ||
| Matthew Smith, Corporate Secretary | ||
| John MacDonald, Director | ||
| Idit Aronsohn, Inclusion Responsibility | ||
| Zohar Zisapel, Independent Director | ||
| Simon Olswang, Independent Director | ||
| Anshoo Gaur, Division President of Amdocs Devel. Center India Pvt Ltd | ||
| Elizabeth McDermon, Secretary and VP of Corporate Strategy of Amdocs Inc. | ||
| Giora Yaron, Director | ||
| Gary Miles, Chief Officer | ||
| Shuky Sheffer, Senior Vice President and President of Customer Business Group, Amdocs Management Limited | ||
| Robert Minicucci, Independent Chairman of the Board | ||
| Mustafa Oyumi, Head Strategy | ||
| Clayton Christensen, Director | ||
| James Kahan, Independent Director | ||
| Rajat Raheja, Division President Amdocs Development Center India Pvt. Ltd | ||
| Avishai Sharlin, GM President | ||
| Adrian Gardner, Independent Director | ||
| Tamar RapaportDagim, Senior Vice President and CFO of Amdocs Management Limited | ||
| John McLennan, Independent Director | ||
| Matt Smith, IR Contact Officer | ||
| Julian Brodsky, Independent Director | ||
| Anthony Goonetilleke, Group Strategy | ||
| Eli Gelman, Director, Member of Technology and Innovation Committee, CEO of Amdocs Management Limited and President of Amdocs Management Limited |
Amdocs Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amdocs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.071 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 10.16 B | ||||
| Shares Outstanding | 116.5 M | ||||
| Shares Owned By Institutions | 97.37 % | ||||
| Number Of Shares Shorted | 1.89 M | ||||
| Price To Earning | 19.03 X | ||||
| Price To Book | 2.81 X |
Pair Trading with Amdocs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amdocs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amdocs will appreciate offsetting losses from the drop in the long position's value.Moving against Amdocs Stock
| 0.72 | NN | Nextnav Acquisition Corp Tech Boost | PairCorr |
| 0.7 | EGIO | Edgio Inc Report 17th of July 2024 | PairCorr |
| 0.59 | GB | Global Blue Group | PairCorr |
| 0.55 | VERI | Veritone Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Amdocs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amdocs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amdocs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amdocs to buy it.
The correlation of Amdocs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amdocs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amdocs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amdocs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Amdocs Stock analysis
When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.18 | Dividend Share 1.74 | Earnings Share 4.68 | Revenue Per Share 41.665 | Quarterly Revenue Growth 0.05 |
The market value of Amdocs is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amdocs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.